Related references
Note: Only part of the references are listed.Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer
J. M. Del Campo et al.
ANNALS OF ONCOLOGY (2009)
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
C. N. Krasner et al.
BRITISH JOURNAL OF CANCER (2007)
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma
Amy Skorupa et al.
CANCER BIOLOGY & THERAPY (2007)
A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
L. Zelek et al.
BRITISH JOURNAL OF CANCER (2006)
Extravasation injury in the perioperative setting
W Schummer et al.
ANESTHESIA AND ANALGESIA (2005)
Phase II study of ET-743 in advanced soft tissue sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
A Le Cesne et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients
A Yovine et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Intrathoracic extravasation of antineoplastic agents -: Case report and systematic review
AK Bozkurt et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2003)
Rituximab therapy for indolent non-Hodgkin's lymphoma
A Hagenbeek et al.
ANTI-CANCER DRUGS (2002)
Retrospective study of the management of chemotherapeutic extravasation injury
HN Langstein et al.
ANNALS OF PLASTIC SURGERY (2002)
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
E Erba et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
